tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Boundless Bio initiated with Early-Stage Biotech at Goldman Sachs

Goldman Sachs analyst Richard Law initiated coverage of Boundless Bio (BOLD) with an Early-Stage Biotech rating, saying the company’s combo approach for its lead asset BBI-355 comes with high risk.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1